-
Daytrading Stocks to Watch for 04/28- SSN, HDY, DRYS, ARNA, IRE, CYCC, SOMX, REDF, AIB, YRCW, SHZ, LLNW, LVLT, JSDA
Thursday, April 28, 2011 - 6:07am | 1534Samson Oil & Gas Limited (AMEX:SSN)- Samson Oil & Gas Limited announced the issuance of 492,400 ordinary fully paid shares at AUD 0.015 per share. The shares were issued pursuant the exercise of listed options. Hyperdynamics Corporation (AMEX:HDY)- Hyperdynamics Corporation, incorporated...
-
Earnings Scheduled For April 28 (MSFT, AET, VIA, XOM, CL, PEP, BMY, MMI, TWC, PG, DOW, S, TYC, CCE, SWY, HOT, EK, EXPE, D, VRSN, EMN)
Thursday, April 28, 2011 - 2:33am | 559Microsoft Corp (NASDAQ: MSFT) is expected to post its FQ3 earnings at $0.56 per share on revenue of $16.20 billion. Aetna Inc (NYSE: AET) is projected to report its Q1 earnings at $0.97 per share on revenue of $8.38 billion. Viacom Inc (NYSE: VIA) is projected to report its FQ2 EPS at $0.61 on...
-
Mad Money Lightning Round: Cramer Likes Apple (MDT, STJ, ABT, MNRO, CMI, WFC, UA, AAPL, AHD)
Thursday, April 28, 2011 - 2:31am | 256On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Medtronic (NYSE: MDT): is “not an exciting stock. I like St Jude Medical (NYSE: STJ). I don't see any catalyst. I think Abbott Laboratories (NYSE: ABT) is better, too." He said that Monro Muffler (NASDAQ: MNRO) “does not belong...
-
VICTRELIS™ Unanimously Recommended for Approval by FDA Advisory Committee (MRK)
Wednesday, April 27, 2011 - 4:54pm | 102Merck (NYSE: MRK) announced today that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration voted unanimously that the available data support approval of Merck's investigational medicine VICTRELIS™ for the treatment of patients with chronic hepatitis C virus genotype 1...
-
FDA Panel Recommends Lip Indication for Medicis' RESTYLANE (MRX)
Wednesday, April 27, 2011 - 4:54pm | 84Medicis (NYSE: MRX) today announced that the U.S. Food and Drug Administration's General and Plastic Surgery Devices Advisory Panel (the Panel) has recommended with a 6-0 vote (1 abstaining) that FDA expand the approved use of RESTYLANE® Injectable Gel, a hyaluronic acid dermal filler, to include...
-
VICTRELIS Unanimously Recommended for Approval by FDA Advisory Committee for Treatment of Chronic HCV Genotype 1 Infection
Wednesday, April 27, 2011 - 4:54pm | 102Merck (NYSE: MRK) announced today that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration voted unanimously that the available data support approval of Merck's investigational medicine VICTRELIS for the treatment of patients with chronic hepatitis C virus genotype 1...
-
U.S. District Court Order Maintains Patent Exclusivity for Lilly's Cymbalta (LLY)
Wednesday, April 27, 2011 - 4:23pm | 73Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has issued an order that prohibits the remaining defendants in the Cymbalta® (duloxetine hydrochloride) patent litigation from selling a generic duloxetine product in the United...
-
Earnings Preview for Bristol Myers Squibb Company (BMY, CTIC)
Wednesday, April 27, 2011 - 4:15pm | 309Bristol Myers Squibb Company (NYSE: BMY) is expected to report its Q1 earnings results on Thursday, April 28, before the markets open. Analysts are predicting earnings per share to be $0.53, slightly below $0.56 recorded last year. Bristol Myers Squibb Company is engaged in the discovery,...
-
Earnings Preview For Celgene Corporation (CELG, NVS)
Wednesday, April 27, 2011 - 4:02pm | 354Celgene Corporation (NASDAQ: CELG) is expected to publish its Q1 earnings on Thursday, April 28, before the markets open. Analysts are expecting earnings per share to stand at $0.80, 27% higher than last year, when the company recorded earnings of $0.63 per share. Two months ago, analysts lowered...
-
CARDIOME PHARMA Up 20% (CRME)
Wednesday, April 27, 2011 - 3:57pm | 79CARDIOME PHARMA CORP (NASDAQ: CRME) shares are soaring today, gaining more than 20% on nearly three times its average daily volume. The company was upgraded by RBC this morning, so this is helping add to the gains. At last check, shares of CARDIOME PHARMA were up 94 cents to $5.35, a gain of 22%...
-
Hepatitis Treatment Wins Over the U.S. FDA Panel -Bloomberg (MRK)
Wednesday, April 27, 2011 - 3:33pm | 37Bloomberg reports that Merck & Co. (NYSE: MRK) wins the U.S. panel's support to sell the hepatitis C drug that cured more patients in clinical trials than current therapies.
-
Biotech /Pharma Stocks Snapshot; Technology and Medical Devices on the Rise Within Healthcare; Aethlon Medical, ELI Lilly (LLY), Medtronic (MDT), Pfizer (PFE), Apple (AAPL)
Wednesday, April 27, 2011 - 3:28pm | 1526Point Roberts, WA - April 27, 2011 - Investorideas.com, a leader in sector stock research including biotech/pharma stocks, reports on new trends in the healthcare sector where the industry is reporting that medical technology is on the rise, and the development of new drugs may be slowing down. The...
-
News Summary
Wednesday, April 27, 2011 - 9:34am | 284Shares of Johnson & Johnson (NYSE: JNJ) dropped about 1.7% after the company announced its plans to purchase US-Swiss medical device maker Synthes Inc for $21.3 billion in cash and stock. JNJ is offering 159 Swiss francs ($181.30) per share for Synthes, representing a 22% premium over the share...
-
J&J's Aaa Rating Outlook To Negative By Moody's (JNJ)
Wednesday, April 27, 2011 - 9:32am | 19J&J's (NYSE: JNJ) Aaa Rating Outlook To Negative By Moody's
-
The Medicines Company Reports EPS of $0.45 vs. $0.40 Estimate; Revenues $112.1M vs. $109.69M Estimate (MDCO)
Wednesday, April 27, 2011 - 8:11am | 23The Medicines Company (NASDAQ: MDCO) Reports EPS of $0.45 vs. $0.40 Estimate; Revenues $112.1M vs. $109.69M Estimate